Goldman Sachs believes Mobia Medical could significantly increase in value due to its unique neurostimulation technology aimed at stroke recovery. The firm set a price target of $31 for the stock, which closed at $13.50 on Monday, suggesting a 130% upside.
Analyst David Roman emphasized the large market opportunity and the company's potential to become a key player in the sector, especially given the high unmet need for effective stroke recovery solutions. Mobia's product, Vivistim, is designed to aid chronic stroke recovery and could potentially benefit around 1 million patients in the U.S.
The stroke incidence rate is approximately 800,000 annually, a figure expected to rise with an aging population. Mobia's stock has already seen a 15% increase since its IPO on May 8, where it was priced at $15, and it rallied 9% following Goldman's positive assessment